BS_JG9JZTA9
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 55.38764783180026
- age_years
- 4.236
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.656
- OXIDATIVE_PHOSPHORYLATION+0.629
- INTERFERON_GAMMA_RESPONSE+0.572
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.560
- ALLOGRAFT_REJECTION+0.527
- IL6_JAK_STAT3_SIGNALING+0.518
- ADIPOGENESIS+0.459
- FATTY_ACID_METABOLISM+0.449
- INFLAMMATORY_RESPONSE+0.395
- MTORC1_SIGNALING+0.385
Top 10 suppressed
- TGF_BETA_SIGNALING-0.285
- SPERMATOGENESIS-0.178
- UV_RESPONSE_DN-0.130
- HEDGEHOG_SIGNALING-0.106
- MITOTIC_SPINDLE-0.099
- KRAS_SIGNALING_DN-0.067
- WNT_BETA_CATENIN_SIGNALING-0.060
- NOTCH_SIGNALING-0.059
- APICAL_JUNCTION-0.044
- PANCREAS_BETA_CELLS-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1078879 | GTEX | — | 0.889 |
| 2 | 0E9EAAED-A9A2-41E7-AC3A-49E94C933432 | — | — | 0.887 |
| 3 | 3BCD8BE5-753D-43EF-B830-EA4356620A5C | — | — | 0.884 |
| 4 | BS_8Z3SCKB5 | subependymal giant cell astrocytoma(SEGA) | — | 0.884 |
| 5 | SJEPD031215_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.878 |
| 6 | BS_M8WP5T16 | low-grade glioma | — | 0.876 |
| 7 | BS_3TQSE8HF | subependymal giant cell astrocytoma(SEGA) | — | 0.875 |
| 8 | 5B9DEC62-3DC7-4DE2-8B20-3E191594FCB4 | — | — | 0.873 |
| 9 | SRR1369148 | GTEX | — | 0.873 |
| 10 | SRR3147741 | — | — | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.656 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.629 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.572 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.560 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.527 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.518 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.459 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.449 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.395 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.385 | Inavolisib | — uncovered |
| COMPLEMENT | 0.381 | Inavolisib | — uncovered |
| APOPTOSIS | 0.379 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.374 | Remibrutinib | — uncovered |
| HYPOXIA | 0.341 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.340 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.337 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.336 | Idelalisib | — uncovered |
| COAGULATION | 0.333 | Binimetinib | — uncovered |
| HEME_METABOLISM | 0.301 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.296 | Inavolisib | — uncovered |